At a glance
| Target | GLP-1 receptor |
|---|---|
| Route | Subcutaneous injection |
| Outcome trial | AMPLITUDE-O |
| New approval | South Korea, October 2026 |
| U.S. status | No FDA approval identified |
Overview
The efpeglenatide development program spans different clinical questions. AMPLITUDE-O tested cardiovascular and renal outcomes in people with type 2 diabetes and substantial baseline risk. Separately, South Korea’s Ministry of Food and Drug Safety announced approval of an efpeglenatide auto-injector on 7 October 2026 for chronic weight management in eligible adults without diabetes, alongside diet and exercise. The catalog reflects this current approval rather than retaining an outdated globally investigational label. However, the jurisdiction and population must remain explicit: Korean obesity authorization does not mean the FDA has approved efpeglenatide or that every trial finding is a labeled claim.
How it works
Efpeglenatide uses an exendin-based GLP-1 agonist linked to a carrier system that extends its action. GLP-1 receptor activation influences appetite, gastric emptying, glucose-dependent insulin secretion and glucagon regulation. Those metabolic mechanisms support development in diabetes and obesity, while cardiovascular and kidney benefits require direct outcomes evidence. A shared GLP-1 target alone would not establish the specific results observed in AMPLITUDE-O.
Current Korean authorization
MFDS states that the efpeglenatide auto-injector was approved on 7 October 2026 for chronic weight management in adults with obesity or qualifying overweight without diabetes, used with dietary and exercise measures.
Supporting sources [1]
Cardiovascular and renal trial results
AMPLITUDE-O randomized 4,076 participants with type 2 diabetes and cardiovascular disease or kidney disease plus additional risk. Major cardiovascular events occurred less often with efpeglenatide, and a prespecified renal composite also improved relative to placebo.
Supporting sources [2]
Different populations answer different questions
The outcome trial involved high-risk diabetes, while the new Korean obesity authorization concerns adults without diabetes. The favorable trial result should not be automatically described as the approved prevention claim for every obesity patient.
Observed adverse effects
Diarrhea, constipation, nausea, vomiting and bloating were more frequent than placebo in AMPLITUDE-O. Current local product information governs contraindications, monitoring and interactions for the approved preparation; the older trial report is not a complete prescribing label.
Supporting sources [2]
Why an older trial-only label is incomplete
Regulatory status changes over time. This record includes the new Korean authorization while retaining the lack of identified FDA approval. Neither label should erase the other jurisdiction’s status or imply immediate commercial access everywhere.
Supporting sources [1]
Reading this profile
Jurisdiction: South Korea — MFDS-approved October 2026 for defined adult weight-management use; no FDA approval identified.. Molecular class: Long-acting exendin-based GLP-1 receptor agonist conjugate.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- MFDS: first domestically developed GLP-1 obesity medicine approval, October 2026 ↗Regulatory source · Checked 2026-10-27
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. ↗Original research · Checked 2026-10-27